SCHEMBL3977050

SCHEMBL3977050

Clc1ncnc2scc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.55
MAPT P10636 5/20 0.55
HTT P42858 3/20 0.55
KMT2A Q03164 1/20 0.55
LMNA P02545 7/20 0.53
ALDH1A1 P00352 3/20 0.53
NPSR1 Q6W5P4 2/20 0.50
FGFR1 P11362 4/20 0.46
DAPK3 O43293 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
ABL1 P00519 1/20 0.46
NTRK1 P04629 1/20 0.46
LCK P06239 1/20 0.46
CSF1R P07333 1/20 0.46
RET P07949 1/20 0.46
MET P08581 1/20 0.46
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
PRKACA P17612 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3980106 0.86 KDR (0.66) KMT2AFGFR1DAPK3PRKD3MAP4K4
SCHEMBL2368374 0.81 SMN1; SMN2 (0.77) SMN1; SMN2MAPTHTTKMT2ALMNA
SCHEMBL3979882 0.77 RAB9A (0.70) SMN1; SMN2KMT2ALMNAALDH1A1NPC1
SCHEMBL3977000 0.74 KDR (0.55) FGFR1PRKD3MAP4K4ABL1NTRK1
SCHEMBL3981430 0.74 KDR (0.55) SMN1; SMN2HTTLMNAFGFR1DAPK3
SCHEMBL14965845 0.74 SMN1; SMN2 (0.70) SMN1; SMN2MAPTHTTKMT2ALMNA
SCHEMBL3982214 0.73 KDR (0.54) SMN1; SMN2LMNAALDH1A1FGFR1DAPK3
SCHEMBL3979887 0.73 KDR (0.67) KMT2ALMNAALDH1A1NPSR1FGFR1
SCHEMBL2369317 0.72 MAPT (1.00) SMN1; SMN2MAPTHTTKMT2ALMNA
SCHEMBL2368934 0.72 SMN1; SMN2 (0.67) SMN1; SMN2MAPTHTTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566721-B2 Substituted thienol[2,3-d]pyrimidines as kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed
US-7566721-B2 Substituted thienol[2,3-d]pyrimidines as kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed
US-7566721-B2 Substituted thienol[2,3-d]pyrimidines as kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed
WO-2008018881-A1 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2008-02-14 WO disclosed
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC., 2007-02-08 US disclosed
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC., 2007-02-08 US disclosed
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC., 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors IGF1R, BRCA1, MAP2K6 SMN1; SMN2 1973/4885MAPT 1585/4885HTT 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.